Evidence map›Paper›PMID 40454188›Full record

ReviewJournal of diabetes and metabolic disorders2025

Advancements in diabetes research and stem cell therapy: a concise review.

Ashlyn Wen Ning Yau, Adeline Yoke Yin Chia

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of diabetes and metabolic disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ashlyn Wen Ning YauSchool of Bioscience, Faculty of Health and Medical Sciences, Taylor's University, Subang Jaya, 47500 Selangor Darul Ehsan Malaysia.
Adeline Yoke Yin ChiaSchool of Bioscience, Faculty of Health and Medical Sciences, Taylor's University, Subang Jaya, 47500 Selangor Darul Ehsan Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus, encompassing both T1DM and T2DM, represents a global health challenge. While traditional therapies focus on managing symptoms, emerging stem cell therapies, particularly MSCs, offer potential curative approaches. This review explores advancements in diabetes research with an emphasis on mesenchymal stem cells (MSCs). Additionally, we discuss clinical trials and applications of MSCs in diabetes treatment, providing a comprehensive analysis of this promising therapeutic frontier. MSCs have been shown to provide immunomodulatory effects, delay disease progression and reverse insulin resistance in preclinical and clinical studies. MSC-derived EVs have been extensively studied as well, exhibiting similar therapeutic benefits while also possibly having lower immunogenicity than MSCs. Phase I and II clinical studies have demonstrated MSCs to be effective in juvenile T1DM and able to significantly reduce HbA1c, fasting blood glucose, insulin demand and plasma blood glucose levels (

Indexed as

Diabetes mellitusExtracellular vesiclesImmunomodulationInsulin resistanceMesenchymal stem cellsStem cell therapy

Identifiers

PMID40454188
PMCPMC12122420

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.